ISIS 2503

Drug Profile

ISIS 2503

Alternative Names: ISIS-2503

Latest Information Update: 10 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 23 Aug 2004 ISIS 2503 is available for licensing (http://www.isispharm.com)
  • 23 Aug 2004 Suspended - Phase-II for Breast cancer in USA (IV-infusion)
  • 23 Aug 2004 Suspended - Phase-II for Colorectal cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top